Crinetics Pharmaceuticals Inc

• Vertex Pharmaceuticals agreed to acquire Crinetics Pharmaceuticals for ten billion dollars cash. • The acquisition includes a premium exceeding one hundred percent of Crinetics' share price. • Executives sold company shares under pre-arranged trading plans during record-high valuations.

• Gilead shares rose following successful Phase 3 HIV trial results. • European regulators approved Trodelvy for first-line cancer monotherapy. • HSBC upgraded Gilead stock to buy, citing an undervalued pipeline.

• Positive MEMBRANE clinical trial results boosted market sentiment for Johnson & Johnson shares. • MedTech division growth and sector-wide capital rotation support the company's recent share gains. • Analysts maintain a Buy rating with an average price target of $254.63.

• JPMorgan increased its Eli Lilly price target citing strong revenue and pipeline growth. • The new Medicare GLP-1 Bridge program expands insurance coverage and boosts patient access. • Analysts expect the company's upcoming earnings to exceed current market consensus estimates.